The Testing Evidence for Using Ivermectin for Treating Canine Osteosarcoma

Executive Summary

• This article covers the evidence I could find for Ivermectin as a treatment for Canine Osteosarcoma.

Introduction

This article provides an overview covering the evidence for Ivermectin versus Canine Osteosarcoma.

In many articles on this site, such as the article How Ivermectin Is Useful for Treating Cancer we covered the evidence for the benefits of Ivermectin for cancer. However, the topic of which specific cancers Ivermectin has been proven effective is a constant source of questions.

There are a lot of quotes in this article, but I have a short one for each cancer type. The article uses the term “IVM” to mean Ivermectin.

About the Brightwork Research Treatment Database

We have a subscription website that provides people with everything they need to know about using Ivermectin for several diseases. Cancer is just one of our most researched areas. To see more see the below article indexes. 

Article Indexes

• Open this link to see just one example Ivermectin article index.
• Open this link to see the full article index. 

We have the most research on Ivermectin and Ivermectin for cancer and are completely independent. However, we have to charge subscribers to stay independent. We have free articles that expose readers to our research and writing -- however most of our content is behind a paywall. 

Cancer Type 15: Canine Osteosarcoma

The following quote is from the article Repurposing Ivermectin to augment chemotherapy’s efficacy in osteosarcoma.

Ivermectin, an anti-protozoal drug, has been shown to have anti-cancer activity. This work investigated the potential of repurposing ivermectin to augment chemotherapy’s efficacy in osteosarcoma.

Ivermectin was effective and acted synergistically with doxorubicin in osteosarcoma cells regardless of cellular origin and genetic profiling. This was achieved through suppressing inhibiting growth and migration, and inducing caspase-dependent apoptosis. Ivermectin also significantly inhibited osteosarcoma growth in vivo and its combination with doxorubicin resulted in much greater efficacy than doxorubicin alone. Importantly, the effective dose of ivermectin was clinically feasible and did not cause significant toxicity in mice. Mechanistical analysis showed that ivermectin induced oxidative stress and damage, and mitochondrial dysfunction.

This is very frequently how Ivermectin has been proven effective against other cancers as well.

Proliferation, migration and apoptosis assays were performed in ivermectin-treated osteosarcoma cells. Combination studies were performed. Osteosarcoma xenograft mouse model was established to investigate the in vivo efficacy of ivermectin. Intracellular reactive oxygen species (ROS) and mitochondrial superoxide, membrane potential, ATP, 8-OHdG level, protein carbonylation and lipid peroxidation were determined after ivermectin treatment.

Ivermectin was effective and acted synergistically with doxorubicin in osteosarcoma cells regardless of cellular origin and genetic profiling. This was achieved through suppressing inhibiting growth and migration, and inducing caspase-dependent apoptosis. Ivermectin also significantly inhibited osteosarcoma growth in vivo and its combination with doxorubicin resulted in much greater efficacy than doxorubicin alone.

Doxorubicin is a chemotherapy drug. Again, it is very common for studies to show the benefits of using Ivermectin along with a chemotherapy drug.

Importantly, the effective dose of ivermectin was clinically feasible and did not cause significant toxicity in mice.

This is also quite typical. Ivermectin has very low toxicity.

Mechanistical analysis showed that ivermectin induced oxidative stress and damage, and mitochondrial dysfunction.

That is — in the cancer cells. Ivermectin disables cancer cells from multiple different mechanisms.

Regarding the dosage and sourcing of Ivermectin, see the article On the Topic of Ivermectin Dosage and Sourcing.

Testing Evidence for Ivermectin

The following quotes are from the article Ivermectin, a potential anticancer drug derived from an antiparasitic drug.

Two Example Areas Where Ivermectin is Proven to Fight Cancer

However, at a high level, two critical and common areas that IVM helps with are the following:

Beneficial Area #1: Ivermectin and Apoptosis

Apostosis is the technical term for programmed cell death. The cells in a body need to respond to chemical messengers, and it is time for cells to die.

Beneficial Area #2: Ivermectin’s Effect on Immunomodulation

Immunomodulation is the calibration of the immune system so that it responds appropriately.

How Ivermectin is Complementary With Conventional Cancer Treatments

IVM not only does not interfere with conventional cancer treatments but there are several treatments; chemotherapy is one example, for which Ivermectin is complementary. I cover this in the topic How Ivermectin Helps Reduce Chemotherapy Drug Resistance in Cancer Cells.